Response to the Letter to the Editor: Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer

2021 ◽  
Author(s):  
Simona Malaspina ◽  
Mikael Anttinen ◽  
Pekka Taimen ◽  
Eliisa Löyttyniemi ◽  
Jukka Kemppainen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Whole Body ◽  
Nodal Staging ◽  
Whole Body Mri ◽  
High Risk Prostate Cancer ◽  
Letter To The Editor ◽  
Prospective Comparison ◽  
Pet Ct ◽  
Risk Prostate Cancer

scholarly journals Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer

2021 ◽  
Author(s):  
Simona Malaspina ◽  
Mikael Anttinen ◽  
Pekka Taimen ◽  
Ivan Jambor ◽  
Minna Sandell ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Lymph Nodes ◽  
The Other ◽  
Imaging Modalities ◽  
Whole Body ◽  
Nodal Staging ◽  
Prospective Comparison ◽  
Contrast Enhanced Ct ◽  
Pet Ct

Abstract Purpose To prospectively compare 18F-prostate-specific membrane antigen (PSMA)-1007 positron emission tomography (PET)/CT, whole-body magnetic resonance imaging (WBMRI) including diffusion-weighted imaging (DWI) and standard computed tomography (CT), in primary nodal staging of prostate cancer (PCa). Methods Men with newly diagnosed unfavourable intermediate- or high-risk PCa prospectively underwent 18F-PSMA-1007 PET/CT, WBMRI with DWI and contrast-enhanced CT within a median of 8 days. Six readers (two for each modality) independently reported pelvic lymph nodes as malignant, equivocal or benign while blinded to the other imaging modalities. Sensitivity, specificity and accuracy were reported according to optimistic (equivocal lesions interpreted as benign) and pessimistic (equivocal lesions interpreted as malignant) analyses. The reference standard diagnosis was based on multidisciplinary consensus meetings where available histopathology, clinical and follow-up data were used. Results Seventy-nine patients completed all the imaging modalities, except for one case of interrupted WBMRI. Thirty-one (39%) patients had pelvic lymph node metastases, which were detected in 27/31 (87%), 14/31 (45%) and 8/31 (26%) patients by 18F-PSMA-1007 PET/CT, WBMRI with DWI and CT, respectively (optimistic analysis). In 8/31 (26%) patients, only 18F-PSMA-1007 PET/CT detected malignant lymph nodes, while the other two imaging modalities were reported as negative. At the patient level, sensitivity and specificity values for 18F-PSMA-1007 PET/CT, WBMRI with DWI and CT in optimistic analysis were 0.87 (95%CI 0.71–0.95) and 0.98 (95%CI 0.89–1.00), 0.37 (95%CI 0.22–0.55) and 0.98 (95%CI 0.89–1.00) and 0.26 (95%CI 0.14–0.43) and 1.00 (95%CI 0.93–1.00), respectively. Conclusion 18F-PSMA-1007 PET/CT showed significantly greater sensitivity in nodal staging of primary PCa than did WBMRI with DWI or CT, while maintaining high specificity. Clinical trial registration Clinicaltrials.gov ID: NCT03537391

18F-Fluorocholine PET Whole-Body MRI in the Staging of High-Risk Prostate Cancer

2018 ◽  
Vol 210 (3) ◽  
pp. 635-640 ◽  
Author(s):  
Ur Metser ◽  
Alejandro Berlin ◽  
Jaydeep Halankar ◽  
Grainne Murphy ◽  
Kartik S. Jhaveri ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Whole Body ◽  
Whole Body Mri ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

11C-Acetate-PET/CT Compared to 99mTc-HDP Bone Scintigraphy in Primary Staging of High-risk Prostate Cancer

2016 ◽  
Vol 36 (12) ◽  
pp. 6475-6480 ◽  
Author(s):  
SARA STRANDBERG ◽  
CAMILLA THELLENBERG KARLSSON ◽  
MATTIAS OGREN ◽  
JAN AXELSSON ◽  
KATRINE RIKLUND
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Bone Scintigraphy ◽  
Primary Staging ◽  
High Risk Prostate Cancer ◽  
Pet Ct ◽  
Risk Prostate Cancer

18F-F-Choline PET/CT in staging of newly diagnosed high-risk prostate cancer

2021 ◽  
Vol 45 (4) ◽  
pp. 223
Author(s):  
Y. Benameur ◽  
O. Ait Sahel ◽  
S. Nabih Oueriagli ◽  
J. El Bekkali ◽  
A. Doudouh
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Newly Diagnosed ◽  
Choline Pet ◽  
High Risk Prostate Cancer ◽  
Pet Ct ◽  
Risk Prostate Cancer

scholarly journals Impact of 68GA-PSMA PET / CT on treatment of patients with recurrent / metastatic high risk prostate cancer - a multicenter study

2018 ◽  
Vol 44 (5) ◽  
pp. 892-899 ◽  
Author(s):  
Aline B. Mattiolli ◽  
Allan Santos ◽  
Andreia Vicente ◽  
Marcelo Queiroz ◽  
Diogo Bastos ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Multicenter Study ◽  
High Risk Prostate Cancer ◽  
Psma Pet ◽  
Pet Ct ◽  
Risk Prostate Cancer

Detection of Lymph Node Metastases in Patients With Prostate Cancer: Comparing Conventional and Digital [18F]-fluorocholine PET-CT Using Histopathology as Reference

2021 ◽  
Author(s):  
Mimmi Bjöersdorff ◽  
Christopher Puterman ◽  
Jenny Oddstig ◽  
Jennifer Amidi ◽  
Sophia Zackrisson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
High Risk ◽  
Lymph Nodes ◽  
Lymph Node Metastases ◽  
Reconstruction Algorithms ◽  
High Risk Prostate Cancer ◽  
Pet Ct ◽  
Risk Prostate Cancer ◽  
Node Metastases

Abstract Background: Positron emission tomography-computed tomography (PET-CT) can be used to detect and stage metastatic lymph nodes in intermediate to high-risk prostate cancer. Improvements to hardware, such as digital technology, and to software, such as reconstruction algorithms, have recently been made. We compared the capability of detecting regional lymph node metastases using conventional and digital silicon photomultiplier (SiPM)-based PET-CT technology for [18F]-fluorocholine (FCH). Extended pelvic lymph node dissection (ePLND) histopathology was used as the reference method.Methods: Retrospectively, a consecutive series of patients with prostate cancer who had undergone staging with FCH PET-CT before ePLND were included. Images were obtained with either a conventional or a SiPM-based PET-CT and compared. FCH uptake in pelvic lymph nodes beyond the uptake in the mediastinal blood pool was considered to be abnormal.Results: One hundred eighty patients with intermediate or high-risk prostate cancer were examined using a conventional Philips Gemini PET-CT (n = 93) between 2015 and 2017 or a digital GE Discovery MI PET-CT (n = 87) from 2017 to 2018. Images that were obtained using the Philips Gemini PET-CT system showed 19 patients (20%) with suspected lymph node metastases compared with 40 patients (46%) using the GE Discovery MI PET-CT. Sensitivity, specificity, and positive and negative predictive value (PPV and NPV) were 0.30, 0.84, 0.47, and 0.72, respectively, for the Philips Gemini and 0.60, 0.58, 0.30, and 0.83, respectively for GE Discovery MI. Area under the curve (AUC) in a receiver operating characteristics (ROC) analysis was similar between the two PET-CT systems (0.58 and 0.58, P = 0.8).Conclusions: A marked difference in sensitivity and specificity was found for the different PET-CT systems, although similar overall diagnostic performance. This is probably due to differences in both hard- and software, including reconstruction algorithms, and should be considered when new technology is introduced.

Sign in / Sign up

Export Citation Format

Share Document